Back to top
more

Mainz Biomed NV (MYNZ)

(Delayed Data from NSDQ)

$1.43 USD

1.43
51,912

-0.02 (-1.38%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $1.43 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of 162.16% and 374.06%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Immunome (IMNM) delivered earnings and revenue surprises of -23.53% and 10.81%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Anika Therapeutics (ANIK) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Anika (ANIK) delivered earnings and revenue surprises of -133.33% and 2.01%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Absci Corporation (ABSI) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Absci Corporation (ABSI) delivered earnings and revenue surprises of -15.79% and 37.93%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fortress Biotech (FBIO) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Fortress Biotech (FBIO) delivered earnings and revenue surprises of 44.70% and 0.49%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

MeiraGTx (MGTX) delivered earnings and revenue surprises of -145.16% and 98.28%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Adma Biologics (ADMA) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Adma Biologics (ADMA) delivered earnings and revenue surprises of 62.50% and 23.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 19.30% and 45.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ANI Pharmaceuticals (ANIP) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

ANI (ANIP) delivered earnings and revenue surprises of 9.68% and 8.16%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 8% and 10.86%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Precigen, Inc. (PGEN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Precigen (PGEN) delivered earnings and revenue surprises of -11.11% and 30.84%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 66.67% and 1.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Kiniksa Pharmaceuticals (KNSA) delivered earnings and revenue surprises of -78.57% and 4.05%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

What Makes Mainz Biomed NV (MYNZ) a New Buy Stock

by Zacks Equity Research

Mainz Biomed NV (MYNZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).